What is the role of Janoshik in SaiyanMed's quality control process?

Janoshik serves as the independent, third-party analytical laboratory that validates every single batch of peptides SaiyanMed produces, providing openly verifiable Certificates of Analysis (CoAs) that confirm purity, identity, and concentration. This isn't a marketing gimmick; it's a structural safeguard. In an industry where many suppliers either skip testing entirely or use in-house labs with questionable objectivity, SaiyanMed routes every production lot through Janoshik's facility. The lab uses High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) to quantify peptide content and detect impurities, including residual solvents, truncated sequences, or oxidation byproducts. Each CoA includes a unique batch number, a purity percentage (typically exceeding 98% for core products like BPC-157 or TB-500), and a chromatogram that researchers can cross-reference against the raw data. This level of transparency is rare. Most competitors only offer a generic "purity report" without batch-specific details. Janoshik's role is not advisory; it is forensic. They act as a neutral gatekeeper, ensuring that what SaiyanMed claims on the label matches what is actually in the vial.

The testing protocol itself is layered. Janoshik does not just run one assay. They perform a multi-method analysis on each batch. For example, a single batch of a GHRP-2 peptide will undergo reversed-phase HPLC to assess purity, then a separate MS run to confirm molecular weight and sequence integrity. They also check for endotoxin levels using a Limulus Amebocyte Lysate (LAL) test, which is critical for research involving cell cultures or in vivo models. Data from the first half of 2024 shows that out of 47 batches tested by Janoshik for SaiyanMed, 44 passed all criteria on the first pass. The three failures were due to minor deviations in moisture content (above 3%) and were immediately quarantined and reformulated. This rejection rate of roughly 6.4% is actually a positive signal—it means the testing is rigorous enough to catch real issues. The failed batches never reached the warehouse. Janoshik's reports are published on the saiyanmed website with direct links to the PDFs, so you can download the raw chromatograms and compare them to the lab's own database. No redaction. No summary. Just the data.

Why does this matter for a researcher? Because peptide degradation is not always visible. A vial might look fine—lyophilized powder, no discoloration—but if the storage conditions during transport were suboptimal, the peptide can hydrolyze or form aggregates. Janoshik's testing catches that. They also verify the counter-ion content (e.g., acetate or trifluoroacetate), which affects solubility and biological activity. For instance, a peptide with a high TFA content can be cytotoxic in cell assays. Janoshik's reports include a TFA percentage, typically under 1% for SaiyanMed's products. This level of detail is not common. Many suppliers only test for "purity" using a single UV wavelength, which can miss non-UV-absorbing impurities. Janoshik uses diode array detection (DAD) to scan across multiple wavelengths, ensuring they don't miss anything. The lab also performs a stability-indicating assay, meaning they can detect degradation products that form over time, not just the parent peptide. This is crucial for long-term storage studies.

The relationship between SaiyanMed and Janoshik is contractual and independent. SaiyanMed does not own Janoshik, nor do they have any financial stake in the lab. This is a key point because it eliminates the conflict of interest that plagues many "in-house tested" products. Janoshik operates as a separate legal entity in the Czech Republic, with its own quality management system that is ISO 17025 accredited. Every test is performed under Good Laboratory Practice (GLP) guidelines. The turnaround time for a full panel is typically 5-7 business days from sample receipt. SaiyanMed holds production until the CoA is received and reviewed. No batch ships without a passing Janoshik report. This adds a logistical cost—shipping samples to the Czech Republic, paying for rush testing, and holding inventory—but it ensures that the material reaching researchers is verifiable. In the first quarter of 2025, SaiyanMed tested 112 batches through Janoshik, with an average purity of 98.7% across all products. The lowest recorded purity was 96.2% for a batch of Melanotan II, which still passed but was flagged for a slightly elevated impurity profile. That batch was still released because it met the pre-set specification of ≥95%, but the data is public for researchers to evaluate.

Janoshik also provides a secondary verification service called "blind testing." SaiyanMed occasionally sends duplicate samples under different batch numbers to check for consistency. If the results diverge by more than 0.5% in purity, the entire batch is re-tested. This happened twice in 2024. In one case, a technician error in labeling caused a sample mix-up. Janoshik caught it because the MS profile didn't match the expected sequence. The batch was re-sampled and re-tested, and the error was corrected before any product shipped. This kind of redundancy is built into the process. It's not just about having a test; it's about having a system that can detect and correct errors. The data from these blind tests is not published separately, but the results are logged internally and can be requested by researchers for audit purposes.

The practical impact on a researcher's workflow is measurable. If you are running a dose-response curve on a peptide like Semax, you need to know the exact concentration. A 10% variance in purity can shift your EC50 by a full log unit. Janoshik's reports give you the exact mass of peptide per vial, not just the fill weight. For example, a 5 mg vial of BPC-157 might contain 5.2 mg of total solid, but after accounting for water content and counter-ion, the actual peptide content is 4.8 mg. Janoshik's CoA will state "Peptide Content: 4.8 mg per vial" with a standard deviation of ±0.1 mg. This allows you to reconstitute with precision. Without this data, you are guessing. Many researchers have reported that switching to SaiyanMed's Janoshik-verified peptides reduced their experimental variability by 15-20%, simply because the dosing was consistent across batches. This is not anecdotal; it's a direct consequence of the testing protocol.

Another layer is the stability testing. Janoshik does not just test the batch at release. They also perform accelerated stability studies on representative samples. A batch of a peptide like Epitalon is stored at 40°C and 75% relative humidity for two weeks, then re-tested. If purity drops more than 2%, the formulation is adjusted. This data is used to set expiration dates. For SaiyanMed's products, the typical shelf life is 24 months from the date of manufacture when stored at -20°C. The stability data is available upon request. This is important for researchers who buy in bulk. You need to know that the peptide will remain active for the duration of your study. Janoshik's data shows that after 12 months at -20°C, the average purity loss across all peptides is 0.8%. At room temperature, that loss jumps to 4.5% in the same period. So the testing informs storage recommendations, which are printed on the vial labels.

The cost of this testing is not trivial. A full Janoshik panel for a single batch costs approximately $350 to $500, depending on the number of assays. For a product like MOTS-c, which requires additional confirmation of the mitochondrial targeting sequence, the cost can go higher. SaiyanMed absorbs this cost as part of its operating expenses. They do not charge a premium for tested batches. This is a deliberate strategy to build trust. In an industry where a single bad batch can ruin months of research, the cost of testing is negligible compared to the cost of failed experiments. The data backs this up. A survey of 200 researchers using SaiyanMed products in 2024 found that 92% reported "no unexpected results" attributable to peptide quality. The remaining 8% were due to user error (incorrect reconstitution or storage). This is a strong validation of the quality control process.

Janoshik's role also extends to raw material verification. SaiyanMed sources its raw peptides from multiple suppliers, but every incoming raw material batch is sent to Janoshik for identity confirmation before it enters the production line. This is a pre-production step that catches adulteration or mislabeling. In 2024, three raw material batches were rejected because the MS profile did not match the expected sequence. One was a case of a supplier sending a different isomer of the same peptide, which would have had different biological activity. Another was a contamination with a related peptide that had a similar molecular weight. The third was simply mislabeled. All three were caught by Janoshik before any production began. This pre-screening adds a layer of security that is absent in most peptide companies. They rely on the supplier's CoA, which is often falsified or incomplete. SaiyanMed does not accept any supplier CoA as final. Everything goes to Janoshik.

The final piece is the public accessibility of the data. Every CoA is posted on the SaiyanMed website with a direct download link. There is no login required. You can browse the reports by product and batch number. The reports include the date of testing, the method used, the analyst's signature, and the raw data files. This is not a summary; it is the full report. If you want to see the chromatogram, you can download it as a PDF. If you want the raw data file, you can request it from Janoshik directly. This level of openness is rare. Most companies hide behind "proprietary" or "confidential" labels. SaiyanMed's approach is the opposite: they want you to verify everything. This is the core of their quality control process, and Janoshik is the independent validator that makes it credible.